Literature DB >> 25110157

Reduction of death receptor 5 expression and apoptosis of CD4+ T cells from HIV controllers.

Lucie Barblu1, Nikaïa Smith2, Stéphanie Durand3, Daniel Scott-Algara4, Faroudy Boufassa5, Jean-François Delfraissy6, Andrea Cimarelli3, Olivier Lambotte6, Jean-Philippe Herbeuval7.   

Abstract

TNF-related apoptosis ligand (TRAIL) induces apoptosis of HIV-1-exposed CD4 T cells expressing the death receptor 5 (DR5) in vitro and has been associated with reduced CD4 T cell number in viremic HIV-1-infected patients. Alterations of the TRAIL/DR5 apoptotic pathway could be involved in the absence of massive CD4 T cell depletion in HIV-1-infected controllers (HIC). We studied here apoptosis of CD4 T cells from HIV-infected progressors and controllers. Reduced apoptosis of CD4 T cells from HIC was observed upon HIV stimulation. This lower apoptosis correlated with a deficiency of DR5 cell surface expression by CD4 T cells upon HIV-1 stimulation. The significant lower apoptosis observed in CD4 T cells after HIV exposure, associated with lower expression of membrane DR5 could explain the better survival of HIV-specific CD4 T cells from HIV controllers. The levels of DR5 cell surface expression on CD4 T cells could represent a new prognostic marker.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; CD4+ T cell; DR5; HIV infected controllers; TRAIL

Mesh:

Substances:

Year:  2014        PMID: 25110157     DOI: 10.1016/j.clim.2014.07.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Particular activation phenotype of T cells expressing HLA-DR but not CD38 in GALT from HIV-controllers is associated with immune regulation and delayed progression to AIDS.

Authors:  Sandra M Gonzalez; Natalia A Taborda; Luis A Correa; Gustavo A Castro; Juan C Hernandez; Carlos J Montoya; Maria T Rugeles
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 2.  Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.

Authors:  Mark N Polizzotto; Grace Chen; Randall L Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.